PMID- 28185656
OWN - NLM
STAT- MEDLINE
DCOM- 20170609
LR  - 20191210
IS  - 1942-5546 (Electronic)
IS  - 0025-6196 (Linking)
VI  - 92
IP  - 3
DP  - 2017 Mar
TI  - Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics, Disease 
      Associations, Treatments, and Outcomes in a Series of 90 Patients at Mayo Clinic, 
      1996-2011.
PG  - 406-414
LID - S0025-6196(16)30769-8 [pii]
LID - 10.1016/j.mayocp.2016.10.030 [doi]
AB  - OBJECTIVE: To characterize the clinical presentation, laboratory studies, disease 
      associations, and treatments of subacute cutaneous lupus erythematosus (SCLE). 
      PATIENTS AND METHODS: A retrospective review of 90 patients with SCLE at Mayo 
      Clinic from January 1, 1996, through October 28, 2011, was performed. RESULTS: 
      The mean patient age at diagnosis was 61 years; 64 patients (71%) were women, and 
      11 cases (12%) were drug induced (1996-2000, no drug-induced cases; 2001-2005, 2 
      cases; 2006-2011, 9 cases). Seventeen of 59 patients (29%) with available data 
      were smokers at the time of diagnosis. The SCLE lesions were photodistributed in 
      75 patients (83%), and 52 (58%) had papulosquamous morphologic findings. 
      Anti-Ro/SS-A positivity was present in 84 of 85 patients tested (99%), whereas 32 
      of the 85 patients (38%) tested positive for anti-La/SS-B. Associated autoimmune 
      connective tissue diseases included Sjogren syndrome (n=13, 14%) and systemic 
      lupus erythematosus (SLE) (n=8, 9%). Eighteen patients (20%) had at least 4 
      American College of Rheumatology criteria for SLE; 1 had lupus nephritis, and 
      none had neurologic or notable hematologic sequelae. The most common therapy was 
      hydroxychloroquine, with a complete response noted in 34 of 46 patients (74%) 
      with available follow-up data. CONCLUSION: Twenty-eight percent of patients with 
      SCLE (n=25) had an associated autoimmune connective tissue disease, although the 
      severe sequelae of SLE, such as nephritis, were rare. The frequency of 
      drug-induced SCLE increased during the study. Most patients responded to 
      treatment with hydroxychloroquine.
CI  - Copyright (c) 2016 Mayo Foundation for Medical Education and Research. Published by 
      Elsevier Inc. All rights reserved.
FAU - Alniemi, Dema T
AU  - Alniemi DT
AD  - Mayo Clinic School of Medicine, Mayo Clinic College of Medicine and Science, Mayo 
      Clinic, Rochester, MN.
FAU - Gutierrez, Albert Jr
AU  - Gutierrez A Jr
AD  - Department of Dermatology, Mayo Clinic, Scottsdale, AZ.
FAU - Drage, Lisa A
AU  - Drage LA
AD  - Department of Dermatology, Mayo Clinic, Rochester, MN.
FAU - Wetter, David A
AU  - Wetter DA
AD  - Department of Dermatology, Mayo Clinic, Rochester, MN. Electronic address: 
      wetter.david@mayo.edu.
LA  - eng
PT  - Journal Article
DEP - 20170206
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings
JID - 0405543
RN  - 0 (Antirheumatic Agents)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - Antirheumatic Agents/therapeutic use
MH  - Drug Hypersensitivity/*complications/drug therapy
MH  - Female
MH  - Humans
MH  - Hydroxychloroquine/*therapeutic use
MH  - *Lupus Erythematosus, Cutaneous/diagnosis/drug therapy/etiology/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Minnesota
MH  - Outcome Assessment, Health Care
MH  - Retrospective Studies
EDAT- 2017/02/12 06:00
MHDA- 2017/06/10 06:00
CRDT- 2017/02/11 06:00
PHST- 2016/07/13 00:00 [received]
PHST- 2016/10/10 00:00 [revised]
PHST- 2016/10/25 00:00 [accepted]
PHST- 2017/02/12 06:00 [pubmed]
PHST- 2017/06/10 06:00 [medline]
PHST- 2017/02/11 06:00 [entrez]
AID - S0025-6196(16)30769-8 [pii]
AID - 10.1016/j.mayocp.2016.10.030 [doi]
PST - ppublish
SO  - Mayo Clin Proc. 2017 Mar;92(3):406-414. doi: 10.1016/j.mayocp.2016.10.030. Epub 
      2017 Feb 6.